Verona Pharma plc (VRNA)
- Previous Close
15.24 - Open
15.86 - Bid 15.26 x 100
- Ask 15.31 x 100
- Day's Range
14.90 - 15.45 - 52 Week Range
11.83 - 23.81 - Volume
494,193 - Avg. Volume
443,259 - Market Cap (intraday)
1.186B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.72 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.29
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
www.veronapharma.comRecent News: VRNA
Performance Overview: VRNA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRNA
Valuation Measures
Market Cap
1.19B
Enterprise Value
965.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.76
Enterprise Value/Revenue
2.53k
Enterprise Value/EBITDA
-18.87
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.64%
Return on Equity (ttm)
-22.67%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-54.37M
Diluted EPS (ttm)
-0.72
Balance Sheet and Cash Flow
Total Cash (mrq)
271.77M
Total Debt/Equity (mrq)
20.59%
Levered Free Cash Flow (ttm)
-36.63M